Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (4)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Kubba, A.
Right arrow Articles by Guillebaud, J
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kubba, A.
Right arrow Articles by Guillebaud, J
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

British Medical Bulletin 49:140-157 (1993)
© 1993 The British Council

research-article

Combined oral contraceptives: acceptability and effective use

A. Kubba and J Guillebaud

Department of Obstetrics and Gynaecology, United Medical and Dental Schools, St Thomas' Hospital London, UK
The Margaret Pyke Centre London, UK

Abstract

With over 60 million users of ‘the pill’ worldwide, safety and efficacy remain the two most relevant issues to both the consumer and the research scientist.

Safety of combined oral contraception (COC) has advanced appreciably. Lessons learned from cohort and case-control studies have been applied to the practical management of oral contraception use, based on screening, selection and regular monitoring of users.

Most health risks of COCs appear to be dependent on the dose and potency (or biological impact) of the constituent steroids. While many of the non-contraceptive benefits of COCs are maintained when modem low dose preparations are used, most, if not all, of the adverse effects have been reduced progressively. Moreover the range of modem hormonal contraceptives has widened with the introduction of a new generation of ‘selective’ progestogens (Desogestrel, Norgestimate and Gestodene), which have minimal androgenicity.

User failure of COCs is still high in many countries. The cause is a combination of poor compliance and anxiety about perceived adverse effects. Compliance can be enhanced by improving the quality of instruction in pill use. Fears of adverse effects of COCs may be allayed through education of users and providers, and sympathetic management of side effects.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.